Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 16/20 | 0.87 |
| ▸ | NTSR2 | O95665 | 15/20 | 0.87 |
| ▸ | SORT1 | Q99523 | 12/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30472155 | 1.00 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL29416842 | 1.00 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL29930119 | 0.94 | NTSR1 (0.87) | NTSR1NTSR2SORT1 | |
| SCHEMBL30880437 | 0.91 | NTSR1 (0.82) | NTSR1NTSR2SORT1 | |
| SCHEMBL31280899 | 0.90 | NTSR1 (0.74) | NTSR1NTSR2SORT1 | |
| SCHEMBL29361023 | 0.90 | NTSR1 (0.74) | NTSR1NTSR2SORT1 | |
| SCHEMBL30034783 | 0.89 | NTSR2 (0.73) | NTSR1NTSR2SORT1 | |
| SCHEMBL30037824 | 0.89 | NTSR2 (0.73) | NTSR1NTSR2SORT1 | |
| SCHEMBL29533517 | 0.88 | NTSR1 (0.82) | NTSR1NTSR2SORT1 | |
| Proctolin SCHEMBL30163458 | 0.87 | NTSR1 (0.71) | NTSR1NTSR2SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329827-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | Alphathera AG (CH) | 2024-03-06 | — | — | EP | claimed |
| WO-2022231424-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | ALPHATHERA AG (CH) | 2022-11-03 | — | — | WO | claimed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | claimed |
| EP-4731658-A1 | TRANSFERRIN RECEPTOR-BINDING MOLECULES, CONJUGATES THEREOF AND THEIR USES TO PREVENT OR TREAT NERVOUS SYSTEM DISEASES | Vect-Horus (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078095-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-19 | — | — | US | disclosed |
| US-20250382633-A1 | ADENOVIRAL VECTORS | UNIV ZUERICH (CH) | 2025-12-18 | — | — | US | disclosed |
| US-12485191-B2 | Radiopharmaceuticals and methods of use thereof | BOARD OF REGENTS OF THE UNIVERISTY OF NEBRASKA (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250332298-A1 | PEPTIDE-COUPLED ALGINATE GELS COMPRISING RADIONUCLIDES | BLUE WAVE THERAPEUTICS GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| US-12453757-B2 | Method for ameliorating autism symptoms by pharmacological activation of the neurotensin receptor 1 (NTSR1) | NEW YORK INSTITUTE OF TECHNOLOGY (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250304677-A1 | Blood-Cerebrospinal Fluid Barrier Crossing Antibodies | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-10-02 | — | — | US | disclosed |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | disclosed |
| EP-3712131-B1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-02-01 | — | — | EP | disclosed |
| WO-2022231424-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | ALPHATHERA AG (CH) | 2022-11-03 | — | — | WO | disclosed |
| US-20220315632-A1 | COMBINATION OF DIETARY PEPTIDES | DIET4LIFE APS (DK) | 2022-10-06 | — | — | US | disclosed |
| US-20220248736-A1 | DIETARY PEPTIDES | DIET4LIFE APS (DK) | 2022-08-11 | — | — | US | disclosed |
| CN-109320502-B | Neurotensin receptor ligands | 3B制药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| US-11259554-B2 | Dietary peptides | DIET4LIFE APS (DK) | 2022-03-01 | — | — | US | disclosed |
| US-20220056077-A1 | DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDE | RATNER, Cecilia (DK) | 2022-02-24 | — | — | US | disclosed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485191-B2 | Radiopharmaceuticals and methods of use thereof | FOLH1, SSTR4, SLC18A2 | NTSR1 139/4885NTSR2 77/4885SORT1 1051/4885 |
| US-12453757-B2 | Method for ameliorating autism symptoms by pharmacological activation of the neurotensin receptor 1 (NTSR1) | NTSR1, NTSR2, NPSR1 | NTSR1 1/4885NTSR2 2/4885SORT1 393/4885 |
| US-20250382633-A1 | ADENOVIRAL VECTORS | DARS1, DBN1, DBNL | NTSR1 2854/4885NTSR2 3498/4885SORT1 532/4885 |
| US-20250332298-A1 | PEPTIDE-COUPLED ALGINATE GELS COMPRISING RADIONUCLIDES | ALG1, ALG3, GRPR | NTSR1 1009/4885NTSR2 1530/4885SORT1 2495/4885 |
| US-11259554-B2 | Dietary peptides | GLP1R, HDGF, VIP | NTSR1 28/4885NTSR2 40/4885SORT1 593/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | NTSR1 5/4885NTSR2 2/4885SORT1 3892/4885 |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | NTSR1 5/4885NTSR2 2/4885SORT1 3892/4885 |
| US-20260078095-A1 | NEUROTENSIN RECEPTOR LIGANDS | NTSR1, NTSR2, GRPR | NTSR1 1/4885NTSR2 2/4885SORT1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.